This trial is evaluating whether Dexcom G6 CGM with CTS will improve 3 primary outcomes and 12 secondary outcomes in patients with Diabetes Mellitus, Type 2. Measurement will happen over the course of During hospitalization (up to 60 days of admission).
This trial requires 100 total participants across 2 different treatment groups
This trial involves 2 different treatments. Dexcom G6 CGM With CTS is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Dexcom g(6) cgm with cts is effective and well tolerated in patients with Type 2 diabetes mellitus and may be an acceptable treatment option in certain patient populations.
Type 2 diabetes is caused by an absolute insulin resistance, which results in insulin deficiency and hyperglycemia. Relative insulin resistance is the cause of prediabetes, and diabetes is caused by the combination of relative and absolute insulin resistance.
Diabetes mellitus, type 2, is the most common form of diabetes in the United States, affecting approximately 8 million adults. Unlike many other forms of diabetes, most diabetes in adults is of the noninsulin-dependent type, with type 2 accounting for about 90% of cases. Diabetes causes many complications, which must be managed carefully to minimize their effect on overall health and long-term health outcomes.
We demonstrated that cure of [type 2 diabetes](https://www.withpower.com/clinical-trials/type-2-diabetes) was not guaranteed. We found that in patients with diabetes diagnosed less than 10 years before the presentation of disease reversal was significantly higher (p<0.0001) than in patients with disease diagnosed 10 or more years prior to the presentation of disease reversal. Furthermore, in multivariate analysis, duration of diabetes prior to presentation was significant independently correlated only at the multivariate level in type 2 diabetic patients. Results from a recent paper suggested that early detection of diabetes was crucial to obtain therapeutic benefit.
The American Diabetes Association estimates that in 2001 more than 25 million Americans will be diagnosed with [type 2 diabetes](https://www.withpower.com/clinical-trials/type-2-diabetes) annually. At least half will be diagnosed by age 45, which is the age at which risk factors become particularly prevalent.
Diabetes mellitus, type 2 is associated with increased peripheral and central obesity, hypertension, and hypercholesterolaemia. A key sign is microalbuminuria (which is a good indicator of the severity of kidney disease), but elevated blood sugar has not been consistently reported. The presence of diabetic nephropathy is highly associated with microalbuminuria.
Type 2 diabetes treatments commonly used include oral medication, insulin injections, and exercise. Type 2 diabetes is also treated with aspirin and other drugs to lower blood cholesterol levels (dyslipidemia), and blood pressure drugs to keep blood pressure at target levels.\n
G6 is a potent insulinotropic peptide and Cgm a potent gluconeogenic peptide and thus, both are important for control of blood glucose concentrations in diabetics. However, G6 is more effective than Cgm in raising post-meal H2o, so G6 should now be considered for this purpose.
Based on these findings, dexcom g6 cgm, when used with proper cts, is safe to use as a treatment plan for people with diabetes mellitus type 2.
Approximately 8% of U.S. adults are diagnosed with DM, type 2, by the year of their 60th birthday. This percentage is decreasing, and therefore, the average age of diagnosis is shifting earlier. If the trends continue, more than half of diabetic adults will be diagnosed by age 45. By 2050, it is unlikely that there will be a significant increase in DM, type 2, since this will become too late to stop high rates of diabetes among infants born to women of low socioeconomic status or of lower ethnic origins.
Dexcom G6-2 with CGM+ alerts in 3x-12months intervals was effective and well tolerated in type 2 diabetes patients with well-controlled hyperglycemia. Results from a recent clinical trial provides the first evidence that Dexcom G6-2 with CGM+ alert and glucose targets is effective in treating T2D with well-controlled hyperglycemia.
In patients treated with dexcom, the most common adverse events reported were gastrointestinal events (n = 13), headache (n = 11), and vomiting (n = 7). Adverse events were reported with a similar frequency for patients on both regimens and tended to appear soon after administration of the medication. Although the majority of patients reported pain on dexcom, this was not reported by any patients receiving insulin glargine. It seems likely that more than one medication or a synergistic effect may be responsible for the gastrointestinal effects observed in this study.